HIV Drug Categories- NNRTIs

Medical Advocates
NNRTIs

Main Page

New and Noteworthy Pediatric Data
General Reports Adolescent/Adult Data
Pharmacokinetics
Diagnostics/Monitoring
Viral Dynamics
Database of ARV Drug Interactions
Hypersusceptibility
Adherence
Resistance Data
Adverse Events
Efficacy

Drugs Main Page HIV Main Page Main New/Newsworthy Home Page

Last Update: December 27, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

December 2008

Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART:
Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
Cuzin L, Allavena C, Morlat P, Dellamonica P.AIDS Rev. 2008 Oct-Dec;10(4):205-11.

General Reports

Journal Papers, Abstracts, and Commentaries

Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART:
Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
Cuzin L, Allavena C, Morlat P, Dellamonica P.
AIDS Rev. 2008 Oct-Dec;10(4):205-11.
Abstract

FULL-TEXT ARTICLE
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate
adherence levels.
Parienti JJ, Das-Douglas M, Massari V, et al
PLoS ONE. 2008 Jul 30;3(7):e2783.
Paper

Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection:
The development pipeline and recent clinical data.
Sweeney ZK, Klumpp K.
Curr Opin Drug Discov Devel. 2008 Jul;11(4):458-70
Abstract

The Current Status of the NNRTI Family of Antiretrovirals Used in the HAART Regime Against HIV Infection.
Martins S, Ramos MJ, Fernandes PA.et al
Curr Med Chem. 2008;15(11):1083-95.
Abstract

Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N, Tachedjian G.
Virus Res. 2008 Mar 25
Abstract

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma
concentrations in HIV-infected patients.
Wyen C, Hendra H, Vogel M, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract

Active Methamphetamine Use is Associated with Transmitted Drug Resistance to Non-Nucleoside
Reverse Transcriptase Inhibitors in Individuals with HIV Infection of Unknown Duration
Cachay ER, Moini N, Kosakovsky Pond SL, et al
Open AIDS J. 2007;1:5-10
Abstract

Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial
Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Shikuma CM, Yang Y, Glesby MJ, et al
J Acquir Immune Defic Syndr. 2007 Jan 22;
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations
among HIV-infected adults in routine clinical practice.
Molto J, Blanco A, Miranda C, Miranda J, et al
Br J Clin Pharmacol. 2007 Jan 12;
Abstract

The Level of Reverse Transcriptase (RT) in Human Immunodeficiency Virus Type 1 Particles
Affects Susceptibility to Nonnucleoside RT Inhibitors but Not to Lamivudine.
Ambrose Z, Julias JG, Boyer PL, et al
J Virol. 2006 Mar;80(5):2578-81.
Abstract

Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease
inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Thomas-Geevarghese A, Raghavan S, Minolfo R, et al
Am J Clin Nutr. 2005 Jul;82(1):146-54.
Abstract

Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based
therapy is effective and well tolerated.
Portsmouth S, Imami N, Pires A, et al.
HIV Med. 2004 Jan; 5(1): 26-9.
Abstract

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease
inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational
studies.
Wood E, Hogg RS, Heath KV, et al A
AIDS. 2003 Dec 5;17(18):2629-2634
Abstract

Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on
Monte Carlo simulations.
Rizzo RC, Udier-Blagovic M, Wang DP
J Med Chem 2002 Jul 4;45(14):2970-87
Abstract

Conference Reports, Abstracts, and Posters

NNRTIs-based HAART in clinical practice. A retrospective study
BM Celesia, L Nigro, S Mavilla,et al
(8th Int Congress on Drug Therapy in HIV Infection)
Abstract

Does gender or ethnicity influence treatment outcomes in antiretroviral naive patients
commencing non-nucleoside reverse transcriptase inhibitor (NNRTI) based HAART?
NT Annan, S Mandalia, M Bower, et al
(8th Int Congress on Drug Therapy in HIV Infection)
Abstract

Gender difference in immunological response to non-nucleoside reverse transcriptase inhibitor
(NNRTI) based regimen in HIV-1 infected Indian patients
K Patel, A Patel, J Patel, et al
(8th Int Congress on Drug Therapy in HIV Infection)
Abstract

Pharmacokinetics Data

Journal Papers, Abstracts, and Commentaries

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside
resistance phenotype
Van Laethem K, Witvrouw M, Pannecouque C, et al.
AIDS 2001 Mar 30;15(5):553-61
Abstract

Diagnostics/Monitoring

Journal Papers, Abstracts, and Commentaries

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse
transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Oct 31;
Abstract

Efficacy Data

Journal Papers, Abstracts, and Commentaries

Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination
with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS, Quinn JB.
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
Abstract

A comparison of three highly active antiretroviral treatment strategies consisting of
non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the
presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058
FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, et al
Lancet. 2006 Dec 16;368(9553):2107-9.
Abstract

Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside
reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R, Fu R, Huffman LH, Korthuis PT.
Lancet. 2006 Oct 28;368(9546):1503-15.
Abstract

The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.
Arribas JR.
J Antimicrob Chemother. 2004 Jul 28
Abstract

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous
system in HIV-1-infected patients.
von Giesen HJ, Koller H, Theisen A, Arendt G.
Acquir Immune Defic Syndr 2002 Apr1;29(4):363-7
Abstract

Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing
and protease inhibitor-containing regimens using observational databases.
Ghani AC, Henley WE, Donnelly CA et al.
AIDS 2001 Jun 15;15(9):1133-42
Abstract

Conference Reports, Abstracts, and Posters

Virologic Failure in Antiretroviral Therapy Naive Patients Is Only Determined by Extreme
Low Values of CD4⁺ Cells or High Values of HIV-1 RNA Concentration, Not by Choice of
Treatment with Nevirapine or Efavirenz
F van Leth, S Andrews, B Grinsztjen, et al
(11 CROI)
Abstract

Viral Dynamics Data

Journal Papers, Abstracts, and Commentaries

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with
regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or
both in INITIO: open-label randomised trial.INITIO Trial
International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, et al
Lancet. 2006 Jul 22;368(9532):287-98
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as
a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced
HIV-Positive Individuals.
Winston A, Amin J, Hales G, et al
AIDS Res Hum Retroviruses. 2006 Apr;22(4):338-41.
Abstract

Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active
Antiretroviral Therapy: Results from the EuroSIDA Study Group.
Mocroft A, Ledergerber B, Viard JP, et al.
J Infect Dis. 2004 Dec 1;190(11):1947-1956.
Abstract

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or
efavirenz-based antiretroviral therapy.
Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
Abstract

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine
or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral
suppression.
Negredo E, Cruz L, Paredes R, et al.
Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract

Hypersusceptibility

Journal Papers, Abstracts, and Commentaries

Drug resistance. NNRTI hypersusceptibility.
Delgado J, Shulman N.
AIDS Read. 2005 Jan;15(1):28-30, 32-4. R
Abstract

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility:
a prospective cohort analysis.
Haubrich RH, Kemper CA, Hellmann NS, et al
AIDS 2002 Oct 18;16(15):F33-40
Abstract

Adherence

Journal Papers, Abstracts, and Commentaries

Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-
Conferring Mutations in NNRTI- or PI-Treated Patients.
Maggiolo F, Airoldi M, Kleinloog HD, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
Abstract

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic
outcomes.
Nachega JB, Hislop M, Dowdy DW, et al
Ann Intern Med. 2007 Apr 17;146(8):564-73
Abstract

Resistance

Journal Papers, Abstracts, and Commentaries

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse
transcriptase.
Ren J, Stammers DK
Virus Res. 2008 Feb 28
Abstract

Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor-Resistant
HIV-1 among Recently Infected Infants Born in the United States.
Persaud D, Palumbo P, Ziemniak C, et al
J Infect Dis. 2007 May 15;195(10):1402-10
Abstract

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in
patients starting and stopping non-nucleoside therapy.
Palmer S, Boltz V, Maldarelli F,et al
AIDS. 2006 Mar 21;20(5):701-710. R
Abstract

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated
HIV-1-infected patients: A French nationwide study.
Masquelier B, Costagliola D, Schmuck A,0.
J Med Virol. 2005 Aug;76(4):441-6.
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be
Demonstrated in Different Assays.
Shulman NS, Delgado J, Bosch RJ, et al
Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81
Abstract

The effect of number of mutations and of drug-class sparing on virological response to salvage
genotype-guided antiretroviral therapy.
Ciancio BC, Trotta MP, Lorenzini P, et al
Antivir Ther. 2003 Dec;8(6):611-6.
Abstract

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling
efavirenz
after nevirapine failure.
Antinori A, Zaccarelli M, Cingolani A, et al.
AIDS Res Hum Retroviruses 2002 Aug 10;18(12):835-8
Abstract

Prevalence of nonnucleoside reverse transcriptase inhibitor(NNRTI) resistance-associated
mutations and polymorphisms inNNRTI-naive HIV-infected patients.
Clevenbergh P, Cua E, Dam E, et al.
HIV Clin Trials 2002 Jan-Feb;3(1):36-44
Abstract

Genotype resistance profiles in patients failing an NNRTI-containing regimen, and
modifications after stopping NNRTI therapy.
Quiros-Roldan E, Airoldi M, Moretti F, et al.
Clin Lab Anal 2002;16(2):76-8
Abstract

Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse
transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse
transcriptase nhibitors.
Auwerx J, North TW, Preston BD,
Mol Pharmacol 2002 Feb;61(2):400-6
Abstract

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside
reverse transcriptase inhibitor-containing regimen.
Delaugerre C, Rohban R, Simon A et al.
J Med Virol 2001 Nov;65(3):445-8
Abstract

Structural mechanisms of drug resistance for mutations at codons181 and 188 in HIV-1
reverse transcriptase and the improved resilience of second generation non-nucleoside
inhibitors.
Ren J, Nichols C, Bird L, Chamberlain P, et al.
J Mol Biol 2001 Sep 28;312(4):795-805
Abstract

Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and
non-nucleoside reverse transcriptase inhibitors.
Torti C, Pozniak A, Nelson M, et al.
J Antimicrob Chemother 2001 Jul;48(1):113-6
Abstract

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in
treatment- experienced HIV-infected patients: impact on virological response to efavirenz-
based therapy.
Shulman N, Zolopa AR, Passaro D, et al.
AIDS 2001 Jun 15;15(9):1125-32
Abstract

International perspectives on antiretroviral resistance. Nonnucleoside reverse
transcriptase inhibitor resistance.
Deeks SG.
J Acquir Immune Defic Syndr 2001 Mar 1;26 Suppl 1:S25-33
Abstract

FULL-TEXT PAPER
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase
resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of
RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
Archer RH, Dykes C, Gerondelis P, Lloyd A,
Virol 2000 Sep;74(18):8390-401
Paper

Conference Reports, Abstracts, and Posters

POSTER
First Low Detectable Viremia (FDV) and Resistance-Associated Mutation under Non
Nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen
JM Chapplain, A Ruffault , N Kerriguy, et al
(1st European Drug Resist. Wkshp)
Poster

POSTER
Mutations at reverse transcriptase codon 103: phenotypic resistance to non-nucleoside
reverse transcriptase inhibitor and clinical correlates
PR Harrigan, et al.
(12 International Drug Resistance Workshop)
Poster

Adverse Events

Journal Papers, Abstracts, and Commentaries

Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active
antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related
metabolic toxicity.
Haddow LJ, Wood CW, Ainsworth JG .
Int J STD AIDS. 2007 May;18(5):343-6.
Abstract

Lipodystrophies related to antiretroviral treatment of HIV infection
Capeau J, Caron M, Vigouroux C,et al
Med Sci (Paris). 2006 May;22(5):531-536.
Abstract

HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase
inhibitor-based regimen.
Martinez V, Marcelin AG, Morini JP, et al
AIDS. 2005 Jul 1;19(10):1065-1069.
Abstract

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N, Dieterich DT.
Semin Liver Dis. 2003 May;23(2):173-82.
Abstract

NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F, Torralba M.
J HIV Ther 2002 Nov;7(Suppl 2):S3-S9
Abstract

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
Palmon R, Koo BC, Shoultz DA, Dieterich DT.
J Acquir Immune Defic Syndr 2002 Apr1;29(4):340-5
Abstract

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders
in human immunodeficiency virus-infected patients.
Chene G, Angelini E, Cotte L, et al.
Clin Infect Dis 2002 Mar 1;34(5):649-57
Abstract

Conference Reports, Abstracts, and Posters

Early Clinical Toxicity to Nonnucleoside Reverse Transcriptase Inhibitor-based HAART in a
Home-based AIDS Care Program in Rural Uganda
F Forna, C Liechty, P Solberg, et al
(13 CROI)
Abstract

Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results from the D:A:D Study
N Friis-M�ller, P Reis, W El-Sadr, et al
(13 CROI)
Abstract

Pediatric Data

Journal Papers, Abstracts, and Commentaries